3SBio's (HKG:1530) unit Shenyang Sunshine Pharmaceutical will obtain the commercialization rights for HER2 ADC drug DB-1303 from Duality Biologics (Shanghai) for various indications in China, Hong Kong, and Macau, a Monday Hong Kong bourse filing said.
Duality Biologics is a clinical-stage innovative biopharmaceutical company mainly engaged in the research and development of antibody-drug conjugates therapeutic agents for the treatment of patients with cancer or autoimmune diseases.
HER2, or Human Epidermal Growth Factor Receptor 2, is a protein that can be found on the surface of some cancer cells.
DB-1303 is designed to treat cancers that have high levels of HER2 expression, such as certain types of breast, gastric, and endometrial cancers. The drug combines an anti-HER2 monoclonal antibody with a topoisomerase I inhibitor, which helps to disrupt the cancer cells' DNA and inhibit their growth.
Shenyang Sunshine will make upfront fees and research, development, and sales milestone payments as part of the cooperation agreement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.